ABBV
艾伯維 AbbVie Inc.
+0.74 (+0.28%)263.25USD712K成交股數465B市值64.5本益比(近四季)7.2股價營收比+10.2%營收年增(近四季)2026-10-29下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 17.0B+10% | 15.0B+12% | 16.6B+10% | 15.8B+9% | 15.4B+7% | 13.3B+8% | 15.1B+6% | 14.5B+4% | 14.5B | 12.3B | 14.3B | 13.9B |
| 營業成本 | 4.3B | 4.2B | – | 5.3B | 4.3B | 4.0B | – | 4.2B | 4.2B | 4.1B | – | 6.5B |
| 毛利 | 12.7B+15% | 10.8B+15% | 12.1B+13% | 10.5B+2% | 11.1B+8% | 9.3B+14% | 10.7B+25% | 10.2B+38% | 10.3B | 8.2B | 8.6B | 7.4B |
| 毛利率 | 74.7% | 71.9% | 72.6% | 66.4% | 71.8% | 70.0% | 70.9% | 70.9% | 70.9% | 66.7% | 60.1% | 53.4% |
| 研發費用 | 2.3B | 2.5B | – | 2.3B | 2.1B | 2.1B | – | 2.1B | 1.9B | 1.9B | – | 1.7B |
| 銷售管理費用 | 3.6B | 3.6B | – | 3.6B | 3.3B | 3.3B | – | 4.2B | 3.4B | 3.3B | – | 3.4B |
| 營業利益 | 6.4B+31% | 4.0B+7% | – | 1.9B-50% | 4.9B+22% | 3.7B+33% | – | 3.8B+68% | 4.0B | 2.8B | – | 2.3B |
| 營業利益率 | 37.9% | 26.6% | – | 12.1% | 31.7% | 28.0% | – | 26.5% | 27.6% | 22.7% | – | 16.4% |
| 稅後淨利 | 3.6B+285% | 695M-46% | 1.8B-8355% | 186M-88% | 938M-32% | 1.3B-6% | −22.0M-103% | 1.6B-12% | 1.4B | 1.4B | 822M | 1.8B |
| 淨利率 | 21.3% | 4.6% | 10.9% | 1.2% | 6.1% | 9.6% | -0.1% | 10.8% | 9.5% | 11.1% | 5.7% | 12.8% |
| 稀釋 EPS | 2.03+290% | 0.39-46% | 1.02-5200% | 0.10-89% | 0.52-32% | 0.72-6% | -0.02-104% | 0.88-12% | 0.77 | 0.77 | 0.46 | 1.00 |
| 稀釋股數 | 1.77B | 1.77B | – | 1.77B | 1.77B | 1.77B | – | 1.77B | 1.77B | 1.77B | – | 1.77B |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 6.6B | 9.4B | 5.2B | 5.6B | 6.5B | 5.2B | 5.5B | 7.3B | 13.1B | 18.1B | 12.8B | 13.3B |
| 應收帳款 | 13.8B | 12.5B | 12.6B | 12.8B | 12.6B | 12.5B | 10.9B | 11.5B | 11.7B | 11.9B | 11.2B | 11.4B |
| 存貨 | 5.1B | 5.0B | 5.0B | 4.9B | 5.0B | 4.5B | 4.2B | 4.5B | 4.2B | 4.2B | 4.1B | 4.0B |
| 總資產 | 135B | 136B | 134B | 134B | 137B | 136B | 135B | 143B | 142B | 149B | 135B | 136B |
| 有息負債 | 62.5B | 64.5B | 64.5B | 63.0B | 63.0B | 64.5B | 66.8B | 58.5B | 58.0B | 63.8B | 59.2B | 55.6B |
| 總負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 股東權益 | −5.9B | −6.7B | −3.3B | −2.6B | −183M | 1.4B | 3.3B | 6.0B | 6.8B | 8.0B | 10.4B | 12.1B |
| 負債比 | – | – | – | – | – | – | – | – | – | – | – | – |
| 淨現金(現金 − 有息負債) | −55.9B | −55.1B | −59.3B | −57.3B | −56.5B | −59.4B | −61.3B | −51.3B | −44.9B | −45.7B | −46.4B | −42.3B |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 3.8B+134% | – | – | – | 1.6B-60% | – | – | – | 4.0B | – | – |
| 資本支出 | – | 265M | – | – | – | 235M | – | – | – | 193M | – | – |
| 自由現金流 | – | 3.6B+155% | – | – | – | 1.4B-64% | – | – | – | 3.8B | – | – |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | 1.5B | – | – | – | 961M | – | – | – | 1.3B | – | – |
| 現金股利 | – | 3.1B | – | – | – | 2.9B | – | – | – | 2.8B | – | – |
| 自由現金流率 | – | 23.8% | – | – | – | 10.5% | – | – | – | 31.3% | – | – |
營收拆解 2017 年度 10-K 的分部揭露 · 年增對前一年度
地區2017 年度 · 26.3B
| 美國 | 18.3B | 69.4% | +14.4% |
|---|---|---|---|
| 其他國家 | 4.1B | 15.5% | +5.0% |
| 英國 | 807M | 3.1% | +4.0% |
| 法國 | 730M | 2.8% | +2.4% |
| 加拿大 | 659M | 2.5% | +5.6% |
| 西班牙 | 521M | 2.0% | -11.5% |
| 義大利 | 475M | 1.8% | -9.2% |
| 巴西 | 410M | 1.6% | +15.5% |
| 荷蘭 | 362M | 1.4% | +2.8% |
| 德國 小計 | 1.2B | 4.4% | +4.8% |
| 日本 小計 | 764M | 2.9% | -0.8% |
產品／服務2017 年度 · 22.2B
| HUMIRA | 18.4B | 83.0% | +14.6% |
|---|---|---|---|
| HCV | 1.3B | 5.7% | -16.3% |
| Synagis | 738M | 3.3% | +1.1% |
| Andro Gel | 577M | 2.6% | -14.5% |
| Kaletra | 423M | 1.9% | -23.0% |
| Sevoflurane | 410M | 1.8% | -4.2% |
| Duodopa | 355M | 1.6% | +21.2% |
| Imbruvica 小計 | 2.6B | 11.6% | +40.4% |
| Other Products 小計 | 998M | 4.5% | -18.0% |
| Creon 小計 | 831M | 3.7% | +13.8% |
| Lupron 小計 | 829M | 3.7% | +1.0% |
| Synthroid 小計 | 781M | 3.5% | +2.4% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 61.2B | +8.6% | 4.2B | 6.9% | 2.36 | 17.8B |
| FY2024 | 56.3B | +3.7% | 4.3B | 7.6% | 2.39 | 17.8B |
| FY2023 | 54.3B | -6.4% | 4.9B | 9.0% | 2.72 | 22.1B |
| FY2022 | 58.1B | +3.3% | 11.8B | 20.4% | 6.63 | 24.2B |
| FY2021 | 56.2B | +22.7% | 11.5B | 20.5% | 6.45 | 22.0B |
| FY2020 | 45.8B | +37.7% | 4.6B | 10.1% | 2.72 | 16.8B |
| FY2019 | 33.3B | +1.6% | 7.9B | 23.7% | 5.28 | 12.8B |
| FY2018 | 32.8B | – | 5.7B | 17.4% | 3.66 | 12.8B |